Aktienanalyse zu Biofrontera Inc (BFRI)BFRIBiofrontera Inc

Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Biofrontera Inc is a good buy right now due to its recent strong performance and improving financial metrics. The stock price is currently at $1.59, which is significantly lower than the analyst price target of $3, indicating a potential upside of 88.68%. Additionally, the company has shown a remarkable year-to-date change of +119.31%, reflecting strong momentum. However, investors should be cautious of the negative net income reported in Q1 2026, which was -$0.41 per share, as this indicates ongoing financial challenges that could impact future performance.